UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 57

Sortiert nach

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial

PloS one, 2017-07, Vol.12 (7), p.e0180762-e0180762

2017

Volltextzugriff (PDF)

Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

Proceedings of the National Academy of Sciences - PNAS, 2017-03, Vol.114 (10), p.E1825-E1832

2017

Volltextzugriff (PDF)

A potent Lassa virus antiviral targets an arenavirus virulence determinant

PLoS pathogens, 2018-12, Vol.14 (12), p.e1007439-e1007439

2018

Volltextzugriff (PDF)

Inhibition of alpha 9 alpha 10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

Proceedings of the National Academy of Sciences - PNAS, 2017-03, Vol.114 (10), p.E1825-E1825

2017

Volltextzugriff (PDF)

Kv1.3 blockade by ShK186 modulates CD4+ effector memory T-cell activity of patients with granulomatosis with polyangiitis

Rheumatology (Oxford, England), 2024-01, Vol.63 (1), p.198-208

2024

Volltextzugriff (PDF)

1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A1511-A1511

2023

Volltextzugriff (PDF)

Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway

Journal of virology, 2016-03, Vol.90 (5), p.2372-2387

2016

Volltextzugriff (PDF)

Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases

Toxicon (Oxford), 2012-03, Vol.59 (4), p.529-546

2012

Volltextzugriff (PDF)

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Frontiers in immunology, 2023-12, Vol.14, p.1311658-1311658

2023

Volltextzugriff (PDF)

Extracellular 2′-5′ Oligoadenylate Synthetase Stimulates RNase L-Independent Antiviral Activity: a Novel Mechanism of Virus-Induced Innate Immunity

Journal of Virology, 2010-11, Vol.84 (22), p.11898-11904

2010

Volltextzugriff (PDF)

780 VISTA-101 – A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A877-A877

2023

Volltextzugriff (PDF)

Kv1.3 channel‐blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases

The FASEB journal, 2014-09, Vol.28 (9), p.3952-3964

2014

Volltextzugriff (PDF)

A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response

Vaccine, 2017-04, Vol.35 (15), p.1964-1971

2017

Volltextzugriff (PDF)

Isoflavone Agonists of IRF-3 Dependent Signaling Have Antiviral Activity against RNA Viruses

Journal of Virology, 2012-07, Vol.86 (13), p.7334-7344

2012

Volltextzugriff (PDF)

Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Frontiers in immunology, 2024, Vol.15, p.1365240-1365240

2024

Volltextzugriff (PDF)

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease

The Journal of pharmacology and experimental therapeutics, 2012-09, Vol.342 (3), p.642

2012

Volltextzugriff (PDF)

Association of the FTO Gene With BMI

Obesity (Silver Spring, Md.), 2008-04, Vol.16 (4), p.902-904

2008

Volltextzugriff (PDF)

Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance

Proceedings of the National Academy of Sciences - PNAS, 2013-06, Vol.110 (24), p.E2239-E2248

2013

Volltextzugriff (PDF)

Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis

Frontiers in immunology, 2017-09, Vol.8, p.1205-1205

2017

Volltextzugriff (PDF)

Genomics Hepatitis C virus gets personal

Nature (London), 2009-09, Vol.461 (7262), p.357-358

2009

Volltextzugriff (PDF)

879 A promising cancer immunotherapy target: novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27

Journal for immunotherapy of cancer, 2021-11, Vol.9 (Suppl 2), p.A921-A921

2021

Volltextzugriff (PDF)

Hepatitis C virus gets personal

Nature (London), 2009-09, Vol.461 (7262), p.357-358

2009

Volltextzugriff (PDF)

High-density rhesus macaque oligonucleotide microarray design using early-stage rhesus genome sequence information and human genome annotations

BMC genomics, 2007-01, Vol.8 (1), p.28-28, Article 28

2007

Volltextzugriff (PDF)

CS06-3. Identification of RLR-activating compounds as novel antiviral therapeutics or vaccine adjuvants

Cytokine (Philadelphia, Pa.), 2011-10, Vol.56 (1), p.14-14

2011

Volltextzugriff (PDF)

Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macaca and human

Genome biology, 2005-01, Vol.6 (7), p.R60-R60

2005

Volltextzugriff (PDF)

1 – 25 von 57

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(56)
Dissertationen
(1)

Sprache

Englisch
(57)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(20)
Humans
(17)
Life Sciences & Biomedicine
(16)
Animals
(12)
Immunotherapy
(6)
Mice
(6)
Female
(5)
Biological And Medical Sciences
(4)
Genetics & Heredity
(4)
Immunology
(4)
Kv1.3 Potassium Channel - Antagonists & Inhibitors
(4)
Ligands
(4)
Male
(4)
Molecular Sequence Data
(4)
Multidisciplinary Sciences
(4)
Science & Technology - Other Topics
(4)
Virology
(4)
Amino Acid Sequence
(3)
Biotechnology & Applied Microbiology
(3)
Care And Treatment
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Safety and pharmacodynamics of dalazatide, a Kv1.3 channel inhibitor, in the treatment of plaque psoriasis: A randomized phase 1b trial

Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

A potent Lassa virus antiviral targets an arenavirus virulence determinant

Inhibition of alpha 9 alpha 10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain

Kv1.3 blockade by ShK186 modulates CD4+ effector memory T-cell activity of patients with granulomatosis with polyangiitis

1357 CD27 is a new promising T cell co-stimulatory target for the cancer immunotherapy – development and selection of a lead anti-CD27 agonist antibody

Targeting Innate Immunity for Antiviral Therapy through Small Molecule Agonists of the RLR Pathway

Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Extracellular 2′-5′ Oligoadenylate Synthetase Stimulates RNase L-Independent Antiviral Activity: a Novel Mechanism of Virus-Induced Innate Immunity

780 VISTA-101 – A phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors

Kv1.3 channel‐blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases

A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response

Isoflavone Agonists of IRF-3 Dependent Signaling Have Antiviral Activity against RNA Viruses

Corrigendum: A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease

Association of the FTO Gene With BMI

Selective Kv1.3 channel blocker as therapeutic for obesity and insulin resistance

Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis

Genomics Hepatitis C virus gets personal

879 A promising cancer immunotherapy target: novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27

Hepatitis C virus gets personal

High-density rhesus macaque oligonucleotide microarray design using early-stage rhesus genome sequence information and human genome annotations

CS06-3. Identification of RLR-activating compounds as novel antiviral therapeutics or vaccine adjuvants

Analysis of the Macaca mulatta transcriptome and the sequence divergence between Macaca and human

Suchergebnisse filtern